Notably, the combination of the indicated EHMT2 inhibitor and Erlotinib could robustly retard tumor growth in NSCLC/ER xenograft models by regulating the PTEN/AKT pathway. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.